Allergan plc Credit Rating

Results 1 - 41 Of 41

Page 1 Of 1 Next

Filter By:

Date	Document Type	Title	Source
25 Oct 2019	Rating Action	Moody's assigns Baa2 to AbbVie's exchange note offering	Moody's Investors Service
26 Jun 2019	Credit Opinion	Allergan Plc: Update to credit analysis – acquisition by AbbVie is pending	Moody's Investors Service
15 Feb 2019	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Allergan, Inc.	Moody's Investors Service
08 Nov 2018	Rating Action	Moody's assigns Baa3 to Allergan's notes; stable outlook	Moody's Investors Service
07 Nov 2018	Credit Opinion	Allergan Plc: Update to credit analysis – near term earnings pressure, but solid pipeline	Moody's Investors Service
30 Oct 2018	Announcement	Moody's: Allergan's debt reduction credit positive	Moody's Investors Service
30 Oct 2018	Issuer Comment	Allergan plc: Debt reduction credit positive	Moody's Investors Service
30 Jul 2018	Issuer In-Depth	Allergan plc: Complex capital structure will become simpler over time, but divestiture and M&A strategy raises event risk	Moody's Investors Service
04 Jun 2018	Issuer Comment	Allergan plc: Allergan’s planned divesture of women’s health and infectious disease units would reduce scale and diversity	Moody's Investors Service
20 Apr 2018	Announcement	Moody's: Allergan's strategic review increases event risk	Moody's Investors Service
20 Apr 2018	Issuer Comment	Allergan plc: Strategic review increases event risk	Moody's Investors Service
14 Feb 2018	Credit Opinion	Allergan plc: Updated to credit analysis – near term generic pressures, tempered by strong pipeline	Moody's Investors Service
16 Oct 2017	Announcement	Moody's: Restasis court ruling credit negative for Allergan	Moody's Investors Service
16 Oct 2017	Issuer Comment	Allergan plc: Restasis patent ruling credit negative	Moody's Investors Service
15 Sep 2017	Issuer In-Depth	Peer Comparison: Allergan plc and Shire plc: Stronger cash flow and liquidity plus lower exposure to new competitive threats give Allergan the edge	Moody's Investors Service
23 May 2017	Rating Action	Moody's assigns Baa3 to Allergan's euro notes; stable outlook	Moody's Investors Service
06 Apr 2017	Credit Opinion	Allergan Plc: Updated Discussion of Key Credit Factors	Moody's Investors Service
13 Feb 2017	Announcement	Moody's: Allergan's ZELTIQ acquisition credit negative on high pricetag	Moody's Investors Service
13 Feb 2017	Issuer Comment	Allergan Plc: Zeltiq acquisition credit negative on high pricetag	Moody's Investors Service
21 Dec 2016	Issuer Comment	Allergan Plc: Acquisition of LifeCell Makes Strategic Sense but Valuation Looks Rich	Moody's Investors Service
02 Nov 2016	Announcement	Moody's: Allergan's Share Repurchase and Dividend Announcement are Credit Negative: No Impact to Ratings	Moody's Investors Service
02 Nov 2016	Issuer Comment	Allergan Plc: Allergan’s Share Repurchase and Dividend Announcement are Credit Negative: No Impact to Ratings	Moody's Investors Service
11 May 2016	Announcement	Moody's: Allergan's Share Repurchase Announcement is Credit Negative	Moody's Investors Service
11 May 2016	Issuer Comment	Allergan Plc: Allergan’s Share Repurchase Announcement is Credit Negative	Moody's Investors Service
14 Apr 2016	Issuer In-Depth	Allergan Plc: After Generics Sale, Allergan Won't Sit on its Cash for Long	Moody's Investors Service
08 Apr 2016	Credit Opinion	Allergan Plc: Update to Allergan's Key Rating Factors Following Termination of Pfizer Deal	Moody's Investors Service
05 Apr 2016	Issuer Comment	Pfizer Inc. and Allergan Plc: New Treasury Rules Create Uncertainty for Deal	Moody's Investors Service
29 Oct 2015	Announcement	Moody's: Potential Pfizer/Allergan combination credit positive	Moody's Investors Service
30 Jul 2015	Issuer Comment	Teva Will Triple Debt to Buy Allergan's Generics Business	Moody's Investors Service
23 Jun 2015	Credit Opinion	Allergan Plc	Moody's Investors Service
17 Jun 2015	Rating Action	Moody's affirms Allergan's Baa3 rating; outlook is stable	Moody's Investors Service
22 Apr 2015	Rating Action	Moody's downgrades bonds of Allergan to Baa3	Moody's Investors Service
02 Mar 2015	Rating Action	Moody's assigns Baa3 rating to Actavis' senior notes	Moody's Investors Service
25 Feb 2015	Credit Focus	Global Pharmaceuticals: Actavis' Performance On-Track Ahead of $22B Bond Offering for Allergan	Moody's Investors Service
18 Nov 2014	Credit Focus	US Pharmaceuticals: Actavis Inc: Allergan Deal Adds Significant Debt, But Business Profile Supports Investment Grade
07 Oct 2014	Announcement	Moody's: Actavis' deal for Durata strategically sound but signals continued M&A risk	Moody's Investors Service
12 Aug 2014	Credit Focus	Actavis: With Modest Organic Revenue Growth, Cost-Cutting Will Drive EBITDA	Moody's Investors Service
10 Jun 2014	Credit Focus	Actavis: All Baa3-Debt is Not Created Equal	Moody's Investors Service
28 Apr 2014	Announcement	Moody's: Forest Lab's acquisition of Furiex is Credit Negative for Actavis	Moody's Investors Service
18 Feb 2014	Rating Action	Moody's Affirms Actavis' Baa3; stable outlook	Moody's Investors Service
01 Nov 2013	Special Comment	FDA Move to Restrict Certain Pain Relievers is Credit Negative for Generic Drug Makers	Moody's Investors Service

Results 1 - 41 Of 41

Page 1 Of 1 Next

Research & Ratings

Products & Solutions

News & Events

Registered User

Not Registered Yet?

Moody's Integrity Hotline

Via the Internet:

By telephone from the United States:

By telephone from outside the United States: